Investors Capital Advisory Services’s Jazz Pharmaceuticals JAZZ Stock Holding History

Investors Capital Advisory Services’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-1,160	Closed	-$204K	–	747
2015 Q2	$204K	Sell	1,160 -5	-0.4%	-$898	0.04%	609
2015 Q1	$201K	Sell	1,165 -119	-9%	-$20.4K	0.04%	618
2014 Q4	$210K	Sell	1,284 -265	-17%	-$44K	0.04%	568
2014 Q3	$248K	Hold	1,549	–	–	0.05%	493
2014 Q2	$227K	Buy	+1,549	New	+$215K	0.04%	552

Other funds holding JAZZ

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

WBC

Westpac Banking Corp Sydney, Australia $1.44B AUM 28.5% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Investors Capital Advisory Services's JAZZ Position: Q3 2015 in Review

Investors Capital Advisory Services sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2015, closing a stake of 1,160 shares — an estimated $204K sold.

Investors Capital Advisory Services first reported a position in JAZZ in Q2 2014 and held it in 5 quarters. The position peaked at $248K in Q3 2014. 361 funds tracked by Wall St. Rank hold JAZZ as of Q3 2015.

Investors Capital Advisory Services reported no remaining Jazz Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Investors Capital Advisory Services sold 1,160 Jazz Pharmaceuticals shares in Q3 2015, an estimated $204K.
Investors Capital Advisory Services first reported a position in Jazz Pharmaceuticals in Q2 2014 and held it in 5 quarters.
Investors Capital Advisory Services's Jazz Pharmaceuticals position peaked at $248K in Q3 2014.
361 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2015.

Based on Investors Capital Advisory Services's 13F filing for Q3 2015, filed 17 Nov 2015.